We conclude that CIP2A inactivation renders cancer cells vulnerable to mitotic errors, which may represent a promising therapeutic target in combination with anti-mitotic agents or against chromosomally unstable or DNA-repair-deficient tumours. The gene discussed is CIP2A; the disease is cancer.